keyword
MENU ▼
Read by QxMD icon Read
search

7 day cycle

keyword
https://www.readbyqxmd.com/read/28319848/treatment-of-premenstrual-dysphoric-disorder-with-the-gabaa-receptor-modulating-steroid-antagonist-sepranolone-uc1010-a-randomized-controlled-trial
#1
Marie Bixo, Karin Ekberg, Inger Sundström Poromaa, Angelica Lindén Hirschberg, Aino Fianu Jonasson, Lotta Andréen, Erika Timby, Marianne Wulff, Agneta Ehrenborg, Torbjörn Bäckström
CONTEXT: Allopregnanolone is a metabolite from progesterone and a positive modulator of the GABAA receptor. This endogenous steroid may induce negative mood in sensitive women when present in serum levels comparable to the premenstrual phase. Its endogenous isomer, isoallopregnanolone, has been shown to antagonize allopregnanolone effects in experimental animal and human models. OBJECTIVE: The objective was to test whether inhibition of allopregnanolone by treatment with the GABAA modulating steroid antagonist (GAMSA) Sepranolone (UC1010) during the premenstrual phase could reduce symptoms of the premenstrual dysphoric disorder (PMDD)...
March 1, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28319587/sedentary-behavior-physical-activity-and-fitness-the-maastricht-study
#2
Jeroen Hpm van der Velde, Annemarie Koster, Julianne D van der Berg, Simone Js Sep, Carla Jh van der Kallen, Pieter C Dagnelie, Miranda T Schram, Ronald Ma Henry, Simone Jpm Eussen, Martien Cjm van Dongen, Coen DA Stehouwer, Nicolaas C Schaper, Hans Hcm Savelberg
PURPOSE: This cross-sectional study examined the mutual independent associations of sedentary behavior, lower intensity physical activity (LPA) and higher intensity physical activity HPA (an approximation of moderate to vigorous physical activity (MVPA) with cardio-respiratory fitness (CRF). METHODS: 2,024 participants were included from The Maastricht Study (mean±SD age: 59.7±8.1 years, 49.6% men). With the activPAL3 activity monitor we assessed sedentary time (ST), sedentary pattern variables (number of sedentary breaks, average sedentary bout duration, and number of prolonged sedentary bouts (≥30 min)), LPA, and HPA...
March 18, 2017: Medicine and Science in Sports and Exercise
https://www.readbyqxmd.com/read/28318974/long-distance-range-expansion-and-rapid-adjustment-of-migration-in-a-newly-established-population-of-barn-swallows-breeding-in-argentina
#3
David W Winkler, Facundo A Gandoy, Juan I Areta, Marshall J Iliff, Eldar Rakhimberdiev, Kevin J Kardynal, Keith A Hobson
When bird populations spread, long-distance pioneering populations are often backfilled by a more slowly advancing front [1-3]. The Barn Swallow Hirundo rustica, a globally distributed passerine [4, 5], expanded its breeding range an exceptional 7,000 km when it began breeding 35 years ago in its regular wintering range in Argentina [6], subsequently expanding over 500 km from its starting point [7-11]. Trans-hemispheric breeding attempts have occurred previously in related swallows [12-14], but only this colonization has lasted...
March 15, 2017: Current Biology: CB
https://www.readbyqxmd.com/read/28314788/the-parp-inhibitor-veliparib-can-be-safely-added-to-bendamustine-and-rituximab-and-has-preliminary-evidence-of-activity-in-b-cell-lymphoma
#4
Jacob D Soumerai, Andrew D Zelenetz, Craig Moskowitz, M Lia Palomba, Paul A Hamlin, Ariela Noy, David J Straus, Alison J Moskowitz, Anas Younes, Matthew J Matasar, Steven Horwitz, Carol Portlock, Jason Konner, Mrinal M Gounder, David M Hyman, Martin H Voss, Matthew G Fury, Devika Gajria, Richard D Carvajal, Alan L Ho, Jan H Beumer, Brian Kiesel, Zhigang Zhang, Alice Chen, Richard F Little, Christine Jarjies, Thu O Dang, Fallon France, Nishant Mishra, John F Gerecitano
PURPOSE: The PARP inhibitor veliparib enhances the cytotoxicity of alkylating agents. This phase 1 study evaluated veliparib with the bifunctional alkylator bendamustine (VB) in patients with relapsed/refractory lymphoma, multiple myeloma, and solid malignancies, with a cohort expansion of VB with rituximab (VBR) in patients with B-cell lymphomas. EXPERIMENTAL DESIGN: This dose-escalation study evaluated safety, pharmacokinetics and preliminary efficacy of veliparib (20-400 mg BID, days 1-7 of 28-day cycle) and bendamustine (70 and 90 mg/m2 IV, days 1 and 2)...
March 17, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28314258/antimetastatic-efficacy-of-the-combination-of-caffeine-and-valproic-acid-on-an-orthotopic-human-osteosarcoma-cell-line-model-in-nude-mice
#5
Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, Takashi Murakami, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Hiroyuki Tsuchiya, Robert M Hoffman
AIM: We have previously reported that caffeine can enhance chemotherapy efficacy of bone and soft tissue sarcoma via cell-cycle perturbation. Valproic acid has histone deacetylase (HDAC) inhibitory activity. We have also reported the anti-tumor efficacy of combination treatment with caffeine and valproic acid against osteosarcoma primary tumors in a cell-line orthotopic mouse model. MATERIALS AND METHODS: In this study, we performed combination treatment of caffeine and valproic acid on osteosarcoma cell lines in vitro and in spontaneous and experimental lung metastasis mouse models of osteosarcoma...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28304139/efficacy-and-safety-of-weekly-intravenous-nanoparticle-albumin-bound-paclitaxel-for-non-small-cell-lung-cancer-patients-who-have-failed-at-least-two-prior-systemic-treatments
#6
Jianchun Duan, Yueqin Hao, Rui Wan, Sifan Yu, Hua Bai, Tongtong An, Jun Zhao, Zhijie Wang, Minglei Zhuo, Jie Wang
BACKGROUND: The study was conducted to evaluate the efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) treatment in patients with advanced non-small-cell lung cancer (NSCLC) who have undergone multi-line therapy, and to investigate the association of secreted protein acidic and rich in cysteine (SPARC) expression status with clinical outcome. METHODS: Sixty-four patients who received NAB-paclitaxel treatment (130 mg/m(2) on days 1 and 8 of a 21 day cycle) as third line or further systemic treatment from 1 May 2011 to 30 June 2014 were included in this retrospective analysis...
March 17, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28302189/temporal-dynamics-of-rituals-in-obsessive-compulsive-disorder
#7
Robert W Bond, Stephen J Guastello, Andrea D Guastello
Obsessive-compulsive disorder (OCD) is characterized by obsessions, defined as intrusive and persistent thoughts, and compulsions, defined as repetitive ritualistic behaviors that attempt to neutralize the anxiety associated with the obsessions. The present study investigated the patterns of symptoms as they occur over time in order to generate new insights about the triggers to symptoms. Fourteen adult participants who met the DSM-5 criteria for OCD completed 7-day logbooks of daily activities including the times when they engaged in compulsive rituals...
April 2017: Nonlinear Dynamics, Psychology, and Life Sciences
https://www.readbyqxmd.com/read/28299514/prognostic-and-predictive-value-of-circulating-tumor-cells-and-cxcr4-expression-as-biomarkers-for-a-cxcr4-peptide-antagonist-in-combination-with-carboplatin-etoposide-in-small-cell-lung-cancer-exploratory-analysis-of-a-phase-ii-study
#8
Ravi Salgia, R Waide Weaver, Michael McCleod, John R Stille, S Betty Yan, Stephanie Roberson, John Polzer, Amy Flynt, Eyas Raddad, Victoria L Peek, Sameera R Wijayawardana, Suzane L Um, Steve Gross, Mark C Connelly, Carrie Morano, Madeline Repollet, Renouard Sanders, Kurt Baeten, David D'Haese, David R Spigel
Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE) versus CE in extensive-stage disease small cell lung cancer (ED-SCLC). Methods This exploratory analysis of a phase II study evaluated CXCR4 expression in baseline tumor tissue and peripheral blood CTCs and in post-treatment CTCs. Optimum cutoff values were determined for CTC counts and CXCR4 expression in tumors and CTCs as predictors of survival outcome...
March 15, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28299309/two-siblings-with-the-same-severe-form-of-21-hydroxylase-deficiency-but-different-growth-and-menstrual-cycle-patterns
#9
Mariarosaria Lang-Muritano, Karine Gerster, Susanna Sluka, Daniel Konrad
Congenital adrenal hyperplasia (CAH) is one of the most frequent autosomal recessive diseases in Europe. Treatment is a challenge for pediatric endocrinologists. Important parameters to judge the outcome are adult height and menstrual cycle. We report the follow-up from birth to adulthood of two Caucasian sisters with salt-wasting CAH due to the same mutation, homozygosity c.290-13A>G (I2 splice), in the 21-hydroxylase gene. Their adherence to treatment was excellent. Our objective was to distinguish the effects of treatment with hydrocortisone (HC) and fludrocortisone (FC) on final height (FH) from constitutional factors...
2017: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/28298332/impact-of-lifelong-exercise-training-on-endothelial-ischemia-reperfusion-and-ischemic-preconditioning-in-humans
#10
Martijn F H Maessen, Anke Ccm van Mil, Yaïra Straathof, Niels P Riksen, Gerard A P J M Rongen, Maria T E Hopman, Thijs M H Eijsvogels, Dick H J Thijssen
Reperfusion is essential for ischemic tissue survival, but causes additional damage to the endothelium (i.e. ischemia-reperfusion [IR] injury). Ischemic preconditioning (IPC) refers to short repetitive episodes of ischemia that can protect against IR. However, IPC efficacy attenuates with older age. Whether physical inactivity contributes to the attenuated efficacy of IPC to protect against IR injury in older humans is unclear. We tested the hypotheses that lifelong exercise training relates to 1) attenuated endothelial IR and 2) maintained IPC efficacy that protects veteran athletes against endothelial IR...
March 15, 2017: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
https://www.readbyqxmd.com/read/28296276/report-on-an-anti-doping-operation-in-guadeloupe-high-number-of-positive-cases-and-inferences-about-doping-habits
#11
A Marchand, C Buisson, L Martin, J-A Martin, A Molina, D Ressiot
Anti-doping controls in non-major events are relatively infrequent and athletes that compete only in these events are less likely to be controlled. The French Anti-Doping Agency carried out an anti-doping operation during a regional cycling competition in Guadeloupe. The urine and serum samples were analyzed by the French anti-doping laboratory. Out of 42 athletes, 7 were positive for one or more substances prohibited by the World Anti-Doping Agency. Four serum samples contained continuous erythropoietin receptor activator (CERA) and one a recombinant erythropoietin...
March 11, 2017: Drug Testing and Analysis
https://www.readbyqxmd.com/read/28293715/a-phase-1-study-of-gemcitabine-nab-paclitaxel-s-1-gas-combination-neoadjuvant-chemotherapy-for-patients-with-locally-advanced-pancreatic-adenocarcinoma
#12
Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naoya Nakagawa, Shinya Takahashi, Hiroki Ohge, Taijiro Sueda
PURPOSE: To determine a recommended dose for a biweekly combination neoadjuvant chemotherapy including gemcitabine, nab-paclitaxel, and S-1 (GAS) for patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). METHODS: Patients with borderline resectable or unresectable LAPC without distant metastasis were eligible for this study. The planned dosages of gemcitabine (mg/m(2), day 1), nab-paclitaxel (mg/m(2), day 1), and S-1 (mg/day, days 1-7) were 800/100/60-100 at level 1, and 1000/125/60-100 at level 2...
March 14, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28292940/optimising-therapeutic-effect-of-aurora-b-inhibition-in-acute-myeloid-leukemia-with-azd2811-nanoparticles
#13
Nicolas Floc'h, Susan Ashton, Paula Taylor, Dawn Trueman, Emily Harris, Rajesh Odedra, Kim Maratea, Nicola Derbyshire, Jacqueline Caddy, Vivien N Jacobs, Maureen Hattersley, Shenghua Wen, Nicola J Curtis, James E Pilling, Elizabeth J Pease, Simon T Barry
Barasertib (AZD1152), a highly potent and selective aurora kinase B inhibitor, gave promising clinical activity in elderly AML patients. However clinical utility was limited by the requirement for a 7 day infusion. Here we assessed the potential of a nanoparticle formulation of the selective Aurora kinase B inhibitor AZD2811 (formerly known as AZD1152-hQPA) in pre-clinical models of AML. When administered to HL-60 tumor xenografts at a single dose between 25mg/kg and 98.7mg/kg, AZD2811 nanoparticle treatment delivered profound inhibition of tumour growth, exceeding the activity of AZD1152...
March 14, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28291390/efficacy-and-safety-of-anti-trop-2-antibody-drug-conjugate-sacituzumab-govitecan-immu-132-in-heavily-pretreated-patients-with-metastatic-triple-negative-breast-cancer
#14
Aditya Bardia, Ingrid A Mayer, Jennifer R Diamond, Rebecca L Moroose, Steven J Isakoff, Alexander N Starodub, Nikita C Shah, Joyce O'Shaughnessy, Kevin Kalinsky, Michael Guarino, Vandana Abramson, Dejan Juric, Sara M Tolaney, Jordan Berlin, Wells A Messersmith, Allyson J Ocean, William A Wegener, Pius Maliakal, Robert M Sharkey, Serengulam V Govindan, David M Goldenberg, Linda T Vahdat
Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. Patients and Methods We evaluated sacituzumab govitecan in a single-arm, multicenter trial in patients with relapsed/refractory metastatic TNBC who received a 10 mg/kg starting dose on days 1 and 8 of 21-day repeated cycles. The primary end points were safety and objective response rate; secondary end points were progression-free survival and overall survival...
March 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28290652/protein-nanocage-as-a-ph-switchable-pickering-emulsifier
#15
Mridul Sarker, Nikodem Tomczak, Sierin Lim
Encapsulation of active compounds in Pickering emulsions using bioderived protein-based stabilizers holds potential for the development of novel formulations in the fields of foods and cosmetics. We employ a dodecahedron hollow protein nanocage as a pH-switchable Pickering emulsifier. E2 protein nanocages are derived from pyruvate dehydrogenase multienzyme complex from Geobacillus stearothermophilus which adsorb at the oil/water interface at neutral and basic pH's and stabilize the Pickering emulsions, while in the acidic range, at pH ∼4, the emulsion separates into emulsion and serum phases due to flocculation...
March 14, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28290219/2-crisaborole-topical-ointment-for-the-treatment-of-mild-to-moderate-atopic-dermatitis
#16
Alice C Cheape, Dedee F Murrell
Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle...
March 14, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28283674/endometrial-transcriptome-in-recurrent-miscarriage-and-recurrent-implantation-failure
#17
Jin Huang, Hao Qin, Yihua Yang, Xiaoyan Chen, Jiamiao Zhang, Susan Laird, Chi Chiu Wang, Ting Fung Chan, Tin Chiu Li
The endometrium becomes receptive to the embryo only in the mid-luteal phase, but not other stages of the menstrual cycle. Endometrial factors play an important role in implantation. Women with recurrent miscarriage and recurrent implantation failure have both been reported to have altered expression of receptivity markers during the window of implantation. We aimed to compare the gene expression profiles of the endometrium in the window of implantation among women with unexplained recurrent implantation failures (RIF) and unexplained recurrent miscarriages (RM) by RNA sequencing (RNA-Seq)...
March 10, 2017: Reproduction: the Official Journal of the Society for the Study of Fertility
https://www.readbyqxmd.com/read/28283264/uterine-contractility-and-elastography-as-prognostic-factors%C3%A2-for-pregnancy-after-intrauterine-insemination
#18
Nelly Swierkowski-Blanchard, Florence Boitrelle, Laura Alter, Jacqueline Selva, Thibaud Quibel, Antoine Torre
OBJECTIVE: To determine the impact of the frequency and intensity of uterine contractions (UCs) at the time of IUI on subsequent fertility. DESIGN: Observational pilot study. SETTING: University hospital. PATIENT(S): One hundred volunteer women scheduled for IUI between April 2011 and July 2013, in whom UCs were assessed during the ultrasound before IUI. INTERVENTION(S): A two-dimensional sagittal uterus elastography was recorded for 5 minutes...
March 7, 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/28282621/uranium-238-u-induced-ros-and-cell-cycle-perturbations-antioxidant-responses-and-erythrocyte-nuclear-abnormalities-in-the-freshwater-iridescent-shark-fish-pangasius-sutchi
#19
Sathesh Kumar Annamalai, Kantha Deivi Arunachalam
The strategic plan of this study is to analyze any possible radiological impact on aquatic organisms from forthcoming uranium mining facilities around the Nagarjuna Sagar Dam in the future. The predominantly consumed and dominant fish species Pangasius sutchi, which is available year-round at Nagarjuna Sagar Dam, was selected for the study. To comprehend the outcome and to understand the mode of action of (238)U, the fish species Pangasius sutchi was exposed to ¼ and ½ of the LC50 doses of waterborne (238)U in a static system in duplicate for 21 days...
March 2, 2017: Aquatic Toxicology
https://www.readbyqxmd.com/read/28281183/a-phase-1b-dose-expansion-study-of-the-pan-class-i-pi3k-inhibitor-buparlisib-bkm120-plus-carboplatin-and-paclitaxel-in-pten-deficient-tumors-and-with-dose-intensified-carboplatin-and-paclitaxel
#20
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, Alexander Drilon, Bob T Li, Wassim Abida, Gopa Iyer, John F Gerecitano, Mrinal Gounder, James J Harding, Martin H Voss, Vicky Makker, Alan L Ho, Pedram Razavi, Alexia Iasonos, Philip Bialer, Mario E Lacouture, Jerrold B Teitcher, Joseph P Erinjeri, Nora Katabi, Matthew G Fury, David M Hyman
Purpose We previously reported the phase I dose escalation study of buparlisib, a pan-class 1A PI3K inhibitor, combined with platinum/taxane-based chemotherapy in patients with advanced solid tumors. The combination was well tolerated and promising preliminary efficacy was observed in PTEN deficient tumors. This phase I dose expansion study now evaluates buparlisib plus high dose carboplatin and paclitaxel in unselected patients with advanced solid tumors and buparlisib plus standard dose carboplatin and paclitaxel in patients with PTEN deficient tumors (ClinicalTrials...
March 9, 2017: Investigational New Drugs
keyword
keyword
100427
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"